Mohit Manrao: Another milestone for patients with mantle cell lymphoma

Mohit Manrao shared on LinkedIn:

“This post is intended for a US audience:

Today we have achieved another milestone for patients with mantle cell lymphoma (MCL) – a type of non-Hodgkin’s lymphoma affecting almost 4,000 new patients in the US each year.

The US FDA has acknowledged the need for treatment options for patients with MCL and granted Priority Review for AstraZeneca’s investigational therapy for previously untreated adults with this rare and typically aggressive form of cancer.

This patient population urgently requires a new treatment approach. Our hope is that this Priority Review will help us bring forward a new option to patients as quickly as possible.

Read more about today’s news.”

Source: Mohit Manrao/LinkedIn

Mohit Manrao is the SVP and Head of US Oncology at AstraZeneca and President of the AstraZeneca Foundation, where he leads community grant programs. As Executive Sponsor of AstraZeneca’s US Health Equity Initiative, he focuses on reducing healthcare disparities. He also serves as a Board Member of the National Pharmaceutical Council.